Prescription Opioid Addiction Treatment Study (POATS)

This is Archived Content. This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA). View current information on nida.nih.gov.

This was a randomized outpatient study for treatment-seeking participants dependent on prescription opioid analgesics. The primary objective was to determine whether the addition of individual drug counseling to the prescription of buprenorphine/naloxone (Bup/Nx) and Standard Medical Management (SMM) improves outcome. Participants were randomized at the beginning of each of two phases to receive BUP/NX paired with either Standard Medical Management (SMM) or Enhanced Medical Management (EMM; defined as SMM plus individual counseling). Six hundred and fifty three participants were randomized into Phase 1, and 360 participants were randomized into Phase 2.

CTN Protocol ID: 
CTN-0030
DSMB ID: 
DSMB-0030
ClinicalTrials.gov ID: 

Principal Investigator(s)

Roger D. Weiss, M.D.
Division of Alcohol and Drug Abuse
McLean Hospital
115 Mill Street
Belmont, MA 2478
rweiss@mclean.harvard.edu

Walter Ling, M.D.
Director
Integrated Substance Abuse Programs
University of California, Los Angeles
11075 Santa Monica Boulevard
Suite 200
Los Angeles, CA 90025
lwalter@ucla.edu

Static CTPS

Participating Sites